IL2 and myeloid leukemia: By this mechanism, HDC or similar compounds with agonist activity at H2 receptors reduce the expansion of myeloid leukemia cells in murine models in vivo [21] and synergize with IL-2 to trigger the NK-cell-dependent lysis of primary AML cells [10,22].